(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide has been researched along with Cancer of Skin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, IH; Burns, A; Choi, G; Choi, JK; Fagg, R; Gatfield, KM; Lee, CS; Naidoo, AA; Park, M; Park, YH; Powell, AJ; Vidgeon-Hart, M | 1 |
| Bode, AM; Carper, AL; Dong, Z; Kim, MO; Langfald, AK; Li, S; Liu, K; Ma, WY; Reddy, K; Zhang, J; Zhu, F; Zykova, T | 1 |
2 other study(ies) available for (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Cancer of Skin
| Article | Year |
|---|---|
Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment.
Topics: Acrylamides; Animals; Anthracenes; Bridged Bicyclo Compounds, Heterocyclic; Capsaicin; Cell Line; Cell Proliferation; Cell Survival; Cocarcinogenesis; Female; Humans; Keratinocytes; Mice; Mice, Hairless; Piperidines; Primary Cell Culture; Pyridines; Pyrrolidines; Risk; Skin Neoplasms; TRPV Cation Channels; Urea | 2018 |
TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Acrylamides; Animals; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carcinogens; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Cocarcinogenesis; ErbB Receptors; Female; Humans; Keratinocytes; Male; Mice; Mice, Hairless; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin Neoplasms; TRPV Cation Channels | 2011 |